HIV-1 Tat DNA DNA:MVA vaccine
1
BioMed Central Page 1 of 1 (page number not for citation purposes) Retrovirology Open Access Poster presentation Homology of HIV-1 Indian subtype C tat gene with other subtypes correlates with the induction of potent cross clade immune responses following immunization with HIV-1 Indian subtype C mutated and codon optimized tat DNA/MVA vaccine in mice Huma Qureshi*, VVSP Prasad, Bimal K Das and Pradeep Seth Address: Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India * Corresponding author Presence of anti-Tat immune responses in HIV infected individual's correlates inversely with the progression of disease. Thus, we focused on the phylogeny & immuno- genicity of Indian subtype C tat gene. In this study full length HIV-1 tat gene was amplified and sequenced. Based on sequencing data HIV-1 Indian subtype Ctat gene con- sensus sequence was derived, mutated & codon opti- mized. This modified tat gene consensus was used to construct tat DNA/MVA vaccine. Immunogenicity of tat DNA/MVA vaccine was studied in mice and immune responses were evaluated by IFNg ELISpot assay and ELISA. Our tat study sequences depicted maximum hom- ology with HIV-1 subtype C. DNA distances of tat study sequences with consensus sequences of subtype M, C, B&A were 8–10%, 4–6%, 19–21% & 11–18% respec- tively. Mice immunized with tat DNA construct alone developed potent cross clade T cell & antibodyresponses. Magnitude of these immune responses was increased 3 folds in mice immunized with tat DNA/MVA prime boost regimen. Immunogenic regions of Indian subtype CTat protein localize at amino acid (aa)1–20, aa 16–35, aa 31– 50, aa 67–86. Core region(aa 31–50) of Indian subtype CTat protein was found to be immunodominant. In this scenario HIV-1 Indiansubtype Ctat gene appears to be a suitable candidate for future multigene HIV vaccine. from 2006 International Meeting of The Institute of Human Virology Baltimore, USA. 17–21 November, 2006 Published: 21 December 2006 Retrovirology 2006, 3(Suppl 1):P51 doi:10.1186/1742-4690-3-S1-P51 <supplement> <title> <p>2006 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts. A single PDF containing all abstracts in this Supplement is available <a href=" http://www.biomedcentral.com/content/files/pdf/1742-4690-3-S1-full.pdf ">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</url></supplement> © 2006 Qureshi et al; licensee BioMed Central Ltd.
-
Upload
huma-qureshi -
Category
Documents
-
view
105 -
download
3
Transcript of HIV-1 Tat DNA DNA:MVA vaccine
BioMed Central
Page 1 of 1(page number not for citation purposes)
Retrovirology
Open AccessPoster presentationHomology of HIV-1 Indian subtype C tat gene with other subtypes correlates with the induction of potent cross clade immune responses following immunization with HIV-1 Indian subtype C mutated and codon optimized tat DNA/MVA vaccine in miceHuma Qureshi*, VVSP Prasad, Bimal K Das and Pradeep Seth
Address: Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
* Corresponding author
Presence of anti-Tat immune responses in HIV infectedindividual's correlates inversely with the progression ofdisease. Thus, we focused on the phylogeny & immuno-genicity of Indian subtype C tat gene. In this study fulllength HIV-1 tat gene was amplified and sequenced. Basedon sequencing data HIV-1 Indian subtype Ctat gene con-sensus sequence was derived, mutated & codon opti-mized. This modified tat gene consensus was used toconstruct tat DNA/MVA vaccine. Immunogenicity of tatDNA/MVA vaccine was studied in mice and immuneresponses were evaluated by IFNg ELISpot assay andELISA. Our tat study sequences depicted maximum hom-ology with HIV-1 subtype C. DNA distances of tat studysequences with consensus sequences of subtype M, C,B&A were 8–10%, 4–6%, 19–21% & 11–18% respec-tively. Mice immunized with tat DNA construct alonedeveloped potent cross clade T cell & antibodyresponses.Magnitude of these immune responses was increased 3folds in mice immunized with tat DNA/MVA prime boostregimen. Immunogenic regions of Indian subtype CTatprotein localize at amino acid (aa)1–20, aa 16–35, aa 31–50, aa 67–86. Core region(aa 31–50) of Indian subtypeCTat protein was found to be immunodominant. In thisscenario HIV-1 Indiansubtype Ctat gene appears to be asuitable candidate for future multigene HIV vaccine.
from 2006 International Meeting of The Institute of Human VirologyBaltimore, USA. 17–21 November, 2006
Published: 21 December 2006
Retrovirology 2006, 3(Suppl 1):P51 doi:10.1186/1742-4690-3-S1-P51
<supplement> <title> <p>2006 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts. A single PDF containing all abstracts in this Supplement is available <a href=" http://www.biomedcentral.com/content/files/pdf/1742-4690-3-S1-full.pdf ">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</url></supplement>
© 2006 Qureshi et al; licensee BioMed Central Ltd.
